Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about MicroStrategy (MSTR) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.MicroStrategy currently has an averag ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Visa (V) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Visa currently has an average brokerage ...

Core Viewpoint - Argenx SE's stock is experiencing a decline due to serious safety concerns raised by the FDA regarding its drug Vyvgart Hytrulo, particularly related to chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) [1][2] Group 1: FDA Concerns - The FDA has identified severe risks associated with Vyvgart Hytrulo, specifically the worsening of CIDP, which is characterized by inflammation of nerve roots and peripheral nerves [1] - The FDA is currently evaluating the need for potential regulatory action regarding Vyvgart [2] Group 2: Drug Approval and Usage - The European Commission has recently approved Vyvgart 1000mg for subcutaneous injection as a monotherapy for adult patients with progressive or relapsing active CIDP after prior treatments [2] - In April, the FDA approved a self-injection option for Vyvgart Hytrulo for adult patients with generalized myasthenia gravis (gMG) and CIDP [3] Group 3: Stock Performance and Analyst Ratings - Argenx's stock has an average 1-year price target of $753.23, indicating an expected upside of 43.52% [4][6] - There are no bearish recommendations for Argenx, with 13 analysts providing bullish ratings; the highest price target is $1065.0 from Guggenheim, while the lowest is $680.0 from Baird [5][7] - As of the latest check, Argenx's stock is down 6.56% at $523.37 [7]

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about TSMC (TSM) .TSMC currently has an average brokerage recommendation (ABR) o ...

A month has gone by since the last earnings report for Salesforce.com (CRM) . Shares have added about 1.4% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Salesforce.com due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It tu ...

Group 1 - Trade Desk Inc (NASDAQ:TTD) stock increased by 3.2% to $70.21 after Evercore ISI Group upgraded the company to "outperform" from "in line" due to attractive valuation and improved risk-reward ratio [1] - The stock has a quarter-to-date lead of 27.3%, but has decreased by 40.8% so far in 2025, facing overhead pressure at $80 since February while maintaining support above $60 since early May [2] - The stock's Schaeffer's Volatility Index (SVI) of 41% indicates low volatility expectations, sitting in the 11th percentile of its annual range, while the Schaeffer's Volatility Scorecard (SVS) score of 86 suggests historically larger-than-expected price swings [3] Group 2 - A majority of analysts are bullish on TTD, with 10 out of 36 firms still holding a "hold" rating, indicating potential for further upgrades [1] - The stock has remained above the $60 region, supported by its 60-day moving average [2]

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about MongoDB (MDB) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.MongoDB currently has an average brokerage r ...

Shares of casino name PENN Entertainment Inc (NASDAQ:PENN) are enjoying a 9% pop this morning, trading at $19.20, the stock's highest level since early March. Driving today's price action is an upgrade by Citizens JMP from "market perform" to "outperform," with a price target of $24. The firm cited a potential turning point in the equity. Today's bull note marks its second of the week, after the stock received a boost on Monday from JPMorgan Securities. Longer term, PENN has been recovering from its early-A ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Astrazeneca (AZN) .Astrazeneca currently has an average brokerage recommen ...

Core Viewpoint - The article discusses the reliability of Wall Street analysts' recommendations, particularly focusing on Halliburton (HAL), and emphasizes the importance of using these recommendations in conjunction with other analytical tools for making investment decisions [1][5]. Group 1: Halliburton's Brokerage Recommendations - Halliburton has an average brokerage recommendation (ABR) of 1.74, indicating a position between Strong Buy and Buy, based on recommendations from 27 brokerage firms [2]. - Out of the 27 recommendations, 16 are classified as Strong Buy, accounting for 59.3%, while 2 are classified as Buy, making up 7.4% of the total recommendations [2]. Group 2: Limitations of Brokerage Recommendations - Solely relying on brokerage recommendations may not be advisable, as studies indicate they often fail to guide investors effectively towards stocks with high potential for price appreciation [5]. - Analysts from brokerage firms tend to exhibit a strong positive bias in their ratings, with five "Strong Buy" recommendations for every "Strong Sell" recommendation, which may mislead investors [6][10]. Group 3: Zacks Rank vs. ABR - The Zacks Rank is a proprietary stock rating tool that classifies stocks into five groups based on earnings estimate revisions, providing a more reliable indicator of near-term price performance compared to ABR [8][11]. - Unlike ABR, which is based solely on brokerage recommendations, the Zacks Rank is updated frequently to reflect changes in earnings estimates, making it a timely tool for predicting future price movements [12]. Group 4: Current Earnings Estimates for Halliburton - The Zacks Consensus Estimate for Halliburton's current year earnings has declined by 1.2% over the past month to $2.37, indicating growing pessimism among analysts regarding the company's earnings prospects [13]. - This decline in earnings estimates has resulted in a Zacks Rank of 4 (Sell) for Halliburton, suggesting caution despite the Buy-equivalent ABR [14].